Search

Part of breast and ovarian cancer cases develops on the hereditary predisposition, i.e. mutation in one of predisposing genes. Although this proportion is relatively small, 5-10% of all breast and ovarian carcinomas, it represents a group with clearly defined etiologic factor. Predictive analysis of unaffected family members allows to identify individuals at high risk of cancer and to include them into the programme of primary and secondary cancer prevention. Following article presents basic review of the hereditary predisposition to breast and ovarian cancer focusing especially on BRCA1 and BRCA2 genes, which are responsible for almost three-quarters of those hereditary tumours.

The incidence of breast cancer continuously increases in developed countries. The introduction of screening methods such as mammography or ultrasound lead to higher proportion of early diagnosed tumors. However, even in early stage tumors occult neoplastic cells can spread to the organism. Such tumor cells are very likely precursors of distant metastases. Using several monoclonal antibodies against epithelial mucins or cytokeratins on the cell surface could be detected one tumor cell among 10(5) or 10(6) of normal bone marrow cells. These cells are not detectable by routine histopathologic exam. More sensitive but also more costly and technically demanding are PCR assays. The sensitivity might reach almost 1:10(7). Prospective clinical trials using immunocytochemistry have shown that the presence of stained cells in bone marrow is clearly associated with shorter disease free survival and overall survival. In the near future we may use the bone marrow examination for the presence of occult tumor cells in order to improve current staging system or as a surrogate marker in the decision-making in regard to adjuvant systemic therapy or in the assessment of efficacy of adjuvant treatment. The review summarizes contemporary knowledge assembled in preclinical and clinical studies.

The authors submitted a very brief review of some biological properties of iron in particular protein-bound iron and on the immense amount of iron which surrounds us (it is the fourth most frequent element). In the human organism there is no physiological system for iron elimination. Therefore its absorption is regulated and restricted. Some substances promote its absorption, other inhibit it. An important factor in the regulation of iron absorption are the iron reserves of the organism, the amount of dietary iron and the enhanced erythropoiesis (incl. the ineffective one), while reduced erythropoiesis does not affect iron absorption. Ascorbic acid forms chelates with iron and thus remains soluble and can be absorbed despite the alkaline pH in the duodenum. Unbound trivalent iron remains insoluble. An important asset to rational iron therapy are Lauberger's discovery of ferritin (1936), assessment of the iron plasma level (Heilmeyer and Plötner, 1937), Laurell's discovery of transferrin (1947), and Addison's RIA method for assessment of the serum ferritin level (1974). Sideropenia remains the most widespread deficiency in human pathology, sideropenic anaemia the most readily diagnosed anaemia which is, however, most wrongly treated.